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Neurocognitive Function and Health-Related Quality of Life in 
Pediatric Korean Survivors of Medulloblastoma
The neurocognitive function and quality of life of 58 Korean survivors of childhood 
medulloblastoma were assessed after surgery, cranial radiation and chemotherapy. All 
patients were evaluated with a battery of neurocognitive function tests and the Pediatric 
Functional Assessment of Cancer Therapy-Brain Tumor Survivors, which consists of self-
report questionnaires on quality of life. The mean full-scale intelligence quotient (IQ), 
verbal IQ, and performance IQ scores were 90.2, 97.1, and 84.16, respectively. The mean 
memory quotient (MQ) score was 86.78, which was within 1 standard deviation of the 
average score of 100. Processing speed, attention, and executive function showed mild to 
moderate deficits. Intelligence, memory, executive function, visuospatial function, and 
simple motor function were significantly lower in the patients diagnosed before 8 years of 
age compared with those diagnosed after 8. The cognitive deficits in the patients 
diagnosed at younger ages might be related to earlier exposure to craniospinal irradiation 
and chemotherapy. The patient and parent proxy evaluations of attention, fine motor 
function, and quality of life did not differ. We found significant neurocognitive changes in 
a wide range of neurocognitive functional domains in Korean survivors of childhood 
medulloblastoma. Long-term follow-up studies of survivors of childhood medulloblastoma 
beginning at the time of their first diagnosis are required to better understand the deficits 
exhibited by survivors of childhood medulloblastoma, so that intervention strategies and 
treatment refinements that reduce the long-term neurocognitive decline can be developed.
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INTRODUCTION
Half of all pediatric brain tumors are located in the posterior 
fossa, and medulloblastomas account for about 50% of posteri-
or fossa tumors (1). Due to the risk of local disease recurrence 
or central nervous system (CNS) dissemination, patients with 
these tumors receive aggressive treatments, which include max-
imal surgical resections followed by craniospinal irradiation and 
chemotherapy.
 Because of the recent therapeutic advancements and im-
proved survival rates of these patients, there is a growing need 
for evaluations of their neurocognitive outcome, which is an 
important contributor to the quality of life (QOL) of these chil-
dren. Previous studies have shown that a young age at diagno-
sis, surgical complications, and extended CNS irradiation are 
the principal risk factors for impaired neuropsychological out-
come and a decreased QOL in survivors of medulloblastoma 
(2).
 Although many studies of the neurocognitive outcomes of 
survivors of brain tumors have been conducted, most have en-
rolled primarily pediatric patients with heterogeneous brain tu-
mors and few patients with medulloblastomas (3). Ronning et 
al. (4) assessed the cognitive functions of patients with both be-
nign and malignant posterior fossa tumors, and they included 
only 11 patients with medulloblastomas. Similarly, a recent 
study by Maddrey et al. (5) of 10-year survivors of childhood 
brain tumors included only 16 patients with medulloblastomas.
 Moreover, most cross-sectional studies of survivors of me-
dulloblastomas have only evaluated intellectual functioning 
and academic achievements, and they have not examined de-
layed recall or working memory, which are known to be medi-
ated by frontal lobe structures and which are important for ex-
ecutive functioning (6). For example, Reeves et al. (7) only eval-
uated visual attention tasks and auditory verbal memory tasks, 
which therefore prevented comprehensive evaluations of at-
tention and memory processes.
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 Another limitation of the previous studies is that the health-
related quality of life (HRQOL) of the survivors of brain tumors 
was assessed with QOL assessment tools that were not specific 
to brain tumors. Maddrey et al. (5) used the Ferrans and Powers 
QOL Index, which is not a brain tumor-specific tool but rather 
an assessment tool of general well-being. Although the survival 
rate of children with CNS tumors now approaches 70%, the 
HRQOL has not been investigated properly in this population 
(8).
 In Korea, the survival rate of patients with childhood medul-
loblastoma is comparable to that of developed countries (9), 
and there is an increasing need to assess the long-term neuro-
cognitive function and QOL of Korean survivors of childhood 
medulloblastoma. This study aimed to assess the neurocogni-
tive function and QOL of Korean survivors of childhood medul-
loblastoma who underwent surgery, craniospinal radiation, 
and chemotherapy.
MATERIALS AND METHODS
Patients and treatment
This study was a multicenter study that was conducted in 4 in-
stitutions by the Korean Society of Pediatric Neuro-Oncology 
(KSPNO-O082 protocol). Pediatric patients who were diagnosed 
with medulloblastoma and who survived without disease were 
included. Patients with psychiatric disorders or those who un-
derwent hematopoietic stem cell transplantation were exclud-
ed. Patients were enrolled from January 2009 to December 2011.
 All patients underwent surgery, radiotherapy, and/or che-
motherapy, and these treatments involved various protocols. 
The medical records were reviewed to determine each patient’s 
diagnosis, treatments, including surgical procedures, radiother-
apy, and chemotherapy regimens, and long-term complications.
Neuropsychological tests and assessment tools
Neuropsychological testing was scheduled and performed by 
authorized personnel. Interviews of each patient’s health sta-
tus, social functioning, and health habits were done by the same 
research nurse practitioner. The neurocognitive and QOL as-
sessments of each patient were performed in a single session 
that lasted approximately 3 hours by a clinical neuropsycholo-
gist (Table 1).
Intelligence
Patients under the age of 15 years were assessed by the Korean 
Wechsler Intelligence Scale for Children-III (KWISC-III), and 
patients above 16 years were assessed by the Korean Wechsler 
Adult Intelligence Scale (KWAIS) (10). Three intelligence quo-
tients (IQ) (full-scale IQ [FSIQ], verbal scale IQ [VIQ], and per-
formance scale IQ [PIQ]) were calculated, and average IQs were 
defined by scores between 85 and 115.
Verbal attention
The digit span score was used to measure attention efficiency. 
The digit span forward, which is a subtest of the Wechsler Intel-
ligence Scale, required the patients to immediately repeat pro-
gressively longer series of numbers that ranged from 3 to 9 dig-
its in length that were read aloud by the examiner. If series of 
the same length were incorrectly repeated in 2 trials, the task 
was discontinued. The scores ranged from 0 to 14, and higher 
scores indicated better performances (11).
Visual attention
The Color Trail Test 1 (CTT 1) is widely thought to measure sus-
tained attention and detect cognitive impairment (12,13). The 
CTT 1 required the subject to connect a set of circles that were 
numbered 1 through 25 in sequence as rapidly as possible. The 
Table 1. Neuropsychological tests and assessment tools
Classification Test References
Neurocognitive function test
Intelligence
  < 15 yr
  ≥ 16 yr
Korean Wechsler Intelligence Scale for Children-III (KWISC-III)
Korean Wechsler Adult Intelligence Scale (KWAIS)
(10)
Attention
   Verbal attention
   Visual attention
Digit span forward (a Wechsler subtest)
Color trail making test 1 (CTT 1)
(11)
(12,13)
Memory
   Verbal memory
   Nonverbal memory
Rey-Kim Memory Test (RKMT)
K-Auditory verbal learning test (KAVLT)
K-Complex figure test (KCFT)
(14)
(14)
(15)
Executive function
   Verbal tests
   Visual test
Controlled oral word association (COWA)
Digit span backward
Color trails test 2 (CTT 2)
(16)
(10,17)
(11,13)
Motor function
   Fine motor
   Simple motor
Grooved pegboard test
Grip strength test
(16,18)
Health-Related Quality of Life Pediatric functional assessment of cancer therapy-brain tumor survivors (Peds-FACT-BrS) (20,21,30)
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score was determined by the amount of time required to com-
plete the task, and higher scores indicated poor performance.
Memory
The Rey-Kim Memory Test (RKMT) was used to assess verbal 
memory performance with the K-Auditory Verbal Learning Test 
(KAVLT), which is the Korean version of the Rey Verbal Learn-
ing Test (14), and nonverbal memory performance with the K-
Complex Figure Test (KCFT), which is the Korean version of the 
Rey Complex Figure Test (14). The KAVLT required the serial 
learning of a list of 15 unrelated words over 5 consecutive trials, 
with immediate recall required after each trial. After a delay of 
20 minutes, the patient was again required to recall 15 words. 
Following completion of the delayed recall, the patient was asked 
to recall 15 of the 60 words in the original list that was read by 
the examiner. In the KCFT, which is essentially identical to the 
standard version of the Rey Complex Figure Test (15), the pa-
tient was required to copy the figure as accurately as possible 
without a time limit. An immediate recall trial was subsequent-
ly administered. After a delay of 20 minutes, the patient was 
again required to recall the figure. The RKMT yielded scores for 
the KAVLT and KCFT in each trial, and these resulted in nor-
malized standard scores with a normative mean of 10 and a 
standard deviation of 3.3.
Verbal executive function tests
The Controlled Oral Word Association (COWA) required the 
patients to generate as many different words as possible within 
60 seconds (16). First, in the Letter Fluency Test, the children 
were required to name as many words as possible that started 
with the Korean letters of K (ㄱ), S (ㅅ), and O (ㅇ). The scores 
were calculated by summing all of the acceptable words pro-
duced for the 3 letters. Second, for the Category Fluency Test, 
the patients were asked to name as many items as possible in 
the semantic categories of animals and supermarket. The de-
pendent variables were the number of correct responses in each 
category.
 Another subtest, the Digit Span Backward, which is thought 
to assess working memory, was conducted. It required the pa-
tients to repeat a series of numbers that ranged in length from 2 
to 8 digits in reverse sequence immediately after they were read 
aloud by the examiner (10,17). This subtest was discontinued 
and scored with the same procedures as those used in the Digit 
Span Forward subtest. Higher scores indicated better perfor-
mances.
Visual executive function tests
The Color Trails Test 2 (CTT 2) was used to measure cognitive 
flexibility (11,13). Like the CTT 1, this test required the patient 
to connect a set of circles that were numbered 1 through 25 in 
sequence as rapidly as possible, but, in the CTT 2, the numbered 
circles needed to be connected in sequence while alternating 
between the pink and yellow colors. Both trials were scored for 
the frequency of errors.
Motor function
Fine motor dexterity was assessed with the Grooved Pegboard 
Test, which required the patients to place grooved pegs into the 
matching holes as quickly as possible with their dominant or 
nondominant hands (16,18). Simple motor function was mea-
sured with the grip strength of their dominant and nondomi-
nant hands.
Health related quality of life
The Pediatric Functional Assessment of Cancer Therapy-Brain 
Tumor Survivors (PedsFACT-BrS) consists of both patient-re-
ported and parent-reported forms. The same procedures were 
used on all of the scales as those used in the Functional Assess-
ment of Chronic Illness Therapy measurement system (19).
 The PedsFACT-BrS version 2 consists of 4 sets of developmen-
tally appropriate generic core scales and brain tumor survivor-
specific (BSS) modules that measure the HRQOLs of individual 
children or adolescents aged 7-12 or 13-18, respectively. Both 
self-report and parent proxy-report versions of the question-
naires are available, and they both use a 5-point Likert scale 
upon which the patients or parents rate “how true each of the 
following statements have been for you during the past 4 weeks” 
(0, not at all; 1, a little bit; 2, somewhat; 3, quite a bit; and 4, very 
much) (20,21)
 The Korean PedsFACT-BrS version used for patients under 
the age of 12 consists of the following 34 items: 21 generic con-
cerns (physical well-being [PWB, 7 items], emotional well-be-
ing [EWB, 10 items], and social family well-being [SFWB, 5 items]) 
and BSS concerns (12 items). The Korean PedsFACT-BrS ver-
sion used for patients between 13 and 18 years of age consists 
of the following 37 items: 21 generic concerns (PWB [7 items], 
EWB [13 items], and SFWB [5 items]) and BSS concerns (12 
items).
Statistical analyses
All of the patient data were analyzed. The patient data were di-
vided into groups according to initial risk, radiation dose, age at 
diagnosis, and time after diagnosis and compared. The scores 
reflecting the neurocognitive function of each individual were 
converted into standard scores according to the age-related 
means and standard deviations from test standardization norms. 
In both the Wechsler Intelligence Test and RKMT, the standard 
scores had a mean of 100 and a standard deviation of 15. We 
calculated the mean values and standard deviations of each 
group. One-sample t-tests were administered to test the hypoth-
esis that there would be deficits in the scaled scores from the 
subtests of the K-WAIS, K-WISC-III, and RKMT, which were 
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compared with a mean of 10. Because there were no Korean 
norms for the COWA test and motor function tests (both the 
grooved pegboard and grip strength test), we analyzed the raw 
scores of these tests. The t-tests were used to analyze the para-
metric data, while Mann-Whitney U-tests were used to analyze 
the nonparametric data. All of the statistical analyses were per-
formed with SPSS for Windows, version 18 (IBM Corporation, 
Armonk, NY, USA).
Ethics statement
This protocol was approved by the institutional review boards 
of Seoul National University Hospital (H-0812-049-266) and 
each hospital in which the study was performed. Informed con-
sents were obtained from all of the patients or their parents or 
guardians.
RESULTS
Characteristics of the patients and their parents
 Fifty-eight patients were evaluated during the study period. 
Their basic clinical characteristics are summarized in Table 2. 
Their mean age at diagnosis was 8 years (range, 1-22 years). Four-
teen patients were over 10 years old at the time of diagnosis. 
Most of the patients underwent a combination of treatments 
involving surgery, radiotherapy, and/or chemotherapy. De-
tailed data on the radiotherapy were available for 47 patients: 
44 patients underwent craniospinal irradiation, 1 patient un-
derwent additional posterior fossa irradiation, and 2 patients 
underwent additional irradiation of the tumor bed. The 44 pa-
tients who underwent craniospinal irradiation received the fol-
lowing doses between 2,160 and 3,960 cGy: 2,160 cGy (n = 1), 
2,340 cGy (n = 22), 2,520 cGy (n = 2), 2,700 cGy (n = 1), 3,060 
cGy (n = 9), 3,240 cGy (n = 2), 3,600 cGy (n = 6), or 3,960 cGy 
(n = 1). Eighteen patients received radiation doses over 3,000 
cGy, and 7 patients received doses over 3,600 cGy. Among those 
who received doses over 3,000 cGy, 8 patients were under 8 years 
old and 10 were over 10 years old at the time of irradiation.
 The chemotherapy regimens varied, and most of the patients 
were classified as average risk. Thus, the KSPNO-M-051 for av-
erage-risk medulloblastoma (22) was the most common regi-
men used in 11 patients, and 8 drugs in 1 day in 6 patients (23), 
POG 9031 in 6 patients (24), and CCG A9961 in 4 patients (25).
 The mean age of the patients at the time of the neurocogni-
tive function tests was 13.7 years (range, 6-26 years). The time 
after diagnosis was less than 3 years in 13 patients (22.4%) and 
more than 10 years in 11 patients (19.0%). The educational sta-
tuses of the patients at the time of the tests were below high 
school in most (n = 50, 86.2%). In this study, we also collected 
data on the parents, including 5 fathers, 43 mothers, and 10 
mother-father pairs. The mean age of the fathers was 47.3 years, 
and that of the mothers was 43.9 years. The mean duration of 
education was 13.7 years in the fathers and 12.9 years in the 
Table 2. Characteristics of the patients (n = 58)
Characteristics
Patients (n = 58)
Mean (range) No. (%)
Gender
   Male
   Female
36
22
(62.1)
(37.9)
Age at diagnosis
  < 3 yr
   3-7 yr
   8-10 yr
  > 10 yr
8 (1-22)
4
25
15
14
(6.9)
(43.1)
(25.9)
(24.1)
Age at neurocognitive function testing
   6-10 yr
   10-15 yr
   15-20 yr
   20-25 yr
  > 25 yr
13.7 (6-26)
12
29
9
7
1
(20.7)
(50.0)
(15.5)
(12.1)
(1.7)
Time after diagnosis
  < 3 yr
   3-7 yr
   8-10 yr
  > 10 yr
13
20
14
11
(22.4)
(34.5)
(24.1)
(19.0)
Duration of education
   Educational status 
  ≤ high school
  ≥ college graduate
7 (1-15)
50
8
(86.2)
(13.8)
Table 3. Summary of intelligence quotient (IQ) and memory quotient scores in all pa-
tients (n = 58)
Scores Mean (SD)
Mini-
mum
Maxi-
mum
IQ less than 1 SD 
(IQ < 85)
No. (%)
Full-scale IQ 90.20 (19.97) 50 129 11 (19.0)
Verbal IQ 97.10 (18.67) 50 130 7 (12.1)
Performance IQ 84.16 (20.96) 50 131 17 (29.3)
Memory quotient 86.78 (15.67) 45 127 23 (39.7)
SD = standard deviation.
Fig. 1. Mean scores of the KWISC-III and KWAIS subtests of all patients (n = 58). The 
bold horizontal line represents the normal value.
KWISC-III = Korean Wechsler Intelligence Scale for Children-III, KWAIS = Korean Wech-
sler Adult Intelligence Scale, FSIQ = full-scale intelligence quotient, INF = information, 
COM = comprehension, SIM = similarities, ARI = arithmetic, DSP = digit span, DSF = 
digit span forward, DSB = digit span backward, VOC = vocabulary, DS = digit sym-
bol, PC = picture completion, PA = picture arrangement, BD = block design, OA = 
object assembly.
 Fsiq INF COM SIM ARI DSP DSF DSB VOC DS PC PA BD OA
12
11
10
9
8
7
6
5
9.3
8.5
9.5
11.1
9.7 9.8 9.8
6
10
6.2
9.8
7.7
8.9 8.6
Yoo HJ, et al. • Neuropsychological Outcome of Survivors of Childhood Medulloblastoma
1730  http://jkms.org http://dx.doi.org/10.3346/jkms.2016.31.11.1726
Table 4. Means and standard deviations of the patient scores according to age at diagnosis 
Variables
Age at diagnosis
T valueP value< 8 yr (n = 29) ≥ 8 yr (n = 29)
Mean (SD) Mean (SD)
Intelligence
FSIQ 83.31 (18.48) 96.55 (20.21) -2.42*
VIQ 91.41 (18.48) 102.79 (17.33) -2.44*
PIQ 77.72 (16.03) 90.59 (23.48) -2.63*
Information 7.52 (3.33) 9.41 (2.81) -2.32*
Comprehension 8.48 (3.25) 10.59 (3.29) -2.42*
Similarities 11.30 (3.90) 12.24 (2.87) -2.38*
Arithmetic 7.79 (3.18) 11.52 (3.37) -4.33‡
Digit span 9.39 (4.16) 10.10 (3.18) -0.73
Vocabulary 9.03 (3.21) 11.10 (3.47) -2.46*
Digit symbol 4.93 (2.67) 7.41 (3.78) -2.88†
Picture completion 9.10 (3.29) 10.10 (3.17) -1.68
Picture arrangement 6.18 (2.33) 9.07 (3.36) -3.76‡
Block design 7.52 (3.56) 10.28 (3.99) -2.77†
Object assembly 7.28 (3.16) 9.85 (4.01) -2.84†
Memory quotient 84.57 (12.09) 90.48 (18.22) -1.44
Verbal memory
   Auditory verbal learning 1-5 38.28 (7.49) 46.34 (8.97) -3.72‡
   Delayed recall 8.75 (2.67) 10.17 (2.74) -2.41*
   Recognition 13.44 (2.81) 14.24 (1.27) -2.09*
Visual memory
   Immediate recall 13.52 (8.17) 21.14 (9.51) -3.27†
   Delayed recall 11.51 (7.29) 19.48 (8.81) -3.76†
Attention
Verbal (DSF) 9.39 (3.16) 10.24 (3.24) -1.01
Visual (CTT 1) 40.17 (22.78) 42.18 (25.37) -0.32
Executive function
Verbal
   Letter fluency test 17.68 (9.62) 32.21 (10.21) -5.51‡
   Supermarket 10.25 (4.38) 15.14 (5.38) -3.76‡
   Animal 12.46 (4.47) 15.03 (4.66) -2.13*
   Digit span backward 5.07 (2.88) 6.90 (2.59) -2.52*
Visual
   Color trails test 2 76.79 (45.83) 68.25 (41.06) -2.08*
Visuospatial function
Rey complex figure copy 23.97 (10.31) 30.12 (8.72) -2.41*
Motor function
Simple motor
   Dominant hand 18.49 (8.54) 30.57 (12.25) -3.29†
   Nondominant hand 16.42 (8.79) 27.72 (15.94) -2.86†
Fine motor
   Dominant hand 94.57 (47.99) 115.11 (39.82) -1.33
   Nondominant hand 108.50 (32.58) 118.10 (47.23) -0.51
SD = standard deviation, FSIQ = full scale intelligence quotient, VIQ = verbal intelligence quotient, PIQ = performance intelligence quotient, DSF = digit span forward, CTT 1 =  
color trails test 1.
*P < 0.05; †P < 0.01; ‡P < 0.001.
mothers. Most caregivers were currently married (86.8%), and 
91.2% of the parents had educations that exceeded the high 
school level.
Neuropsychological tests and assessments for intelligence
The data on the mean FSIQ, VIQ, and PIQ are summarized in 
Table 3. The mean estimated FSIQ score for the patients in this 
study was 90.2 (range, 50-129), which was within 1 standard 
deviation of the average IQ score of 100. Six patients had stan-
dard deviations above 1 for their average FSIQ score of 115. Elev-
en patients (19.0%) had average FSIQ values below 85, 7 patients 
(12.1%) had average VIQ values below 85, and 17 patients (29.3%) 
had average PIQ values below 85. The mean values of all of the 
KWISC-III and KWAIS subtests are shown in Fig. 1. These data 
revealed values that were lower than normal on the nonverbal 
performance subtests of block design (T = -2.26, P < 0.05), ob-
ject assembly (T = -2.02, P < 0.05), picture arrangement (T =  
-5.51, P < 0.001), and, especially, digit symbol (T = -8.38, P <  
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0.001). For verbal function, the scores for information (T = -3.62, 
P < 0.001) were lower than normal, and the digit span back-
ward scores for visual executive function (T = 10.54, P < 0.001) 
were significantly lower than borderline (mean score = 6.00).
 We compared the scores on the intelligence subtests between 
the patients under 8 years old at diagnosis (Patient Group 1) 
and patients 8 years or older at diagnosis (Patient Group 2) (Ta-
ble 4). The group 1 patients showed significantly lower scores 
than the group 2 patients on all of the tests, except for the digit 
span test. In particular, the arithmetic and picture arrangement 
scores were considerably lower in the patients who were diag-
nosed under the age of 8 years.
Assessments for memory
The mean estimated MQ score for the patients in this study was 
86.78 (range, 45-127), which was within 1 standard deviation of 
the average MQ score of 100 (Table 3). Twenty-three patients 
(39.7%) had MQ values below 1 standard deviation of the aver-
age MQ score of 85. In addition, 5 out of 58 patients (8.6%) dem-
onstrated scores that were 2 standard deviations below the av-
erage MQ score of 100, which indicated impairments in overall 
global memory function. The mean scores on all of the RKMT 
subtests are shown in Fig. 2. Values that were significantly lower 
than normal were found for the following subtests: auditory ver-
bal 1 (T = -4.83, P < 0.001), auditory verbal 3 (T = -4.49, P < 0.001), 
auditory verbal 4 (T = -3.66, P < 0.001), auditory verbal 5 (T =  
-4.64, P = 0.001), verbal delayed recall (T = -4.94, P < 0.001), vi-
sual immediate recall (T = -3.88, P < 0.001), and visual delayed 
recall (T = -4.36, P < 0.001).
 In the comparisons of the memory test scores between the 
patients under 8 at diagnosis (Patient Group 1) and the patients 
8 or older at diagnosis (Patient Group 2), the total MQ did not 
differ between the groups. However, the scores on the other 
verbal memory and visual memory subtests were significantly 
lower in Patient Group 1 (Table 4). Among the memory sub-
tests, the mean scores on the auditory verbal learning 1-5 tests 
were markedly lower in the patients diagnosed under 8.
Assessments for attention
Table 4 shows the mean scores for both age groups. Although 
the differences were not statistically significant, both the verbal 
and visual attention scores for Patient Group 1 were lower than 
those for Patient Group 2.
Assessments for executive function
For both verbal and visual executive functions, the scores of Pa-
tient Group 1 on all of the subtests were lower than those of Pa-
tient Group 2. The mean values for all of the subtests of execu-
tive function are shown in Table 4. These data show that the 
scores in Patient Group 1 were significantly lower than those in 
Patient Group 2 for the following tests: Letter Fluency Test (T =  
-5.51, P < 0.001), Supermarket test (T = -3.76, P < 0.001), Ani-
mal test (T = -2.13, P < 0.05), Digit Span Backward Test (T = -2.13, 
P < 0.05), and CTT 2 (T = -2.08, P < 0.05).
Assessments for visuospatial function
For visuospatial function, the mean score of Patient Group 1 
was lower than that of Patient Group 2 in the Rey complex fig-
ure copy task (T = -2.41, P < 0.05) (Table 4).
Motor functions
For simple motor function, the mean scores of Patient Group 1 
were lower than those of Patient Group 2 for both the dominant 
(T = -3.29, P < 0.01) and nondominant hands (T = -2.86, P < 0.01). 
However, no significant differences were observed for the fine 
motor function tests (Table 4).
Table 5. Means and standard deviations of the health-related quality of life (HRQOL) 
scores according to age at diagnosis
Variables
Age at diagnosis
T value< 8 yr (n = 29) ≥ 8 yr (n = 29)
Mean (SD) Mean (SD)
Patients (n = 58)
   PWB
   SFWB
   EWB
   BSS
   PedsTotal
21.43
16.04
26.36
36.29
100.59
(5.97)
(3.31)
(6.49)
(7.24)
(18.44)
20.32
13.93
23.75
32.71
90.71
(4.82)
(4.86)
(7.27)
(9.77)
(21.48)
0.76
1.89
1.42
1.54
1.82
Fathers (n = 15)
   PWB
   SFWB
   EWB
   BSS
   PedsTotal
20.08
14.14
27.20
34.29
85.40
(6.36)
(6.07)
(15.32)
(10.02)
(37.52)
19.09
11.73
30.50
32.45
96.38
(6.04)
(5.62)
(8.85)
(13.20)
(28.34)
0.36
1.02
-0.49
0.40
0.60
Mothers (n = 53)
   PWB
   SFWB
   EWB
   BSS
   PedsTotal
19.50
12.73
25.82
32.20
89.40
(6.23)
(6.08)
(7.76)
(9.17)
(23.01)
18.96
11.88
30.25
33.11
94.62
(5.92)
(5.61)
(7.05)
(9.35)
(20.09)
0.31
0.52
1.62
-0.31
-0.64
SD = standard deviation, PWB = physical well-being, SFWB = social family well-be-
ing, EWB = emotional well-being, BSS = brain tumor survivor-specific.
Fig. 2. Mean scores on the Rey-Kim memory test of all of the patients (n = 58).
MQ = memory quotient, A1 = auditory verbal 1, A2 = auditory verbal 2, A3 = audito-
ry verbal 3, VD = verbal delayed recall, VR = verbal delayed recognition, VSI = visual 
immediate recall, VSD = visual delayed recall, VC = visual copy.
 MQ A1 A2 A3 A4 A5 VD VR VSI VSD VC
10.0
9.5
9.0
8.5
8.0
7.5
7.0
6.5
6.0
9.1
7.9
9.0
8.3 8.5 8.3
7.9
9.2
7.7
7.5
9.5
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Health related quality of life
In the HRQOL assessment, the PedsTotal scores were 100.59 in 
the patients diagnosed under the age of 8 and 90.71 in the pa-
tients diagnosed over 8 (Table 5). The results on the subtests 
showed slightly higher scores in Patient Group 1 than in Patient 
Group 2. However, the scores did not differ significantly for PWB, 
SFWB, EWB, or BSS. In the parent proxy-reports of the patients, 
the parent scores tended to be lower than those of the patients 
in all of the fields of the HRQOL tests. Like the patients’ scores, 
the mean scores of the fathers and mothers in Patient Group 1 
were slightly higher than those of the father and mothers in Pa-
tient Group 2. However, there were no significant differences in 
the scores on the total PedsFACT-BrS or subscales.
DISCUSSION
This study is the first large-scale study to assess the neurocogni-
tive function and QOL of Korean survivors of childhood medul-
loblastoma. We assessed the intelligence, motor function, ver-
bal and visual memory, executive function, and attention of 
these patients. Furthermore, we assessed the HRQOL of these 
patients with a brain tumor-specific subscale and a pediatric 
Functional Assessment of Cancer Therapy.
 Like other studies, we found significant changes in a wide 
range of neuropsychological functional domains. Maddrey et 
al. (5) examined the neuropsychological performance and QOL 
of 16 survivors of childhood medulloblastoma who survived for 
more than 10 years with similar test batteries and questionnaires 
as those used in the current study. Although the percentage of 
patients who survived more than 10 years in our study was only 
11% (19/58), the mean age of the patients in our study (8 years) 
was similar to the age of the patients in the study of Maddrey et 
al. (7.3 years old) (5). The mean estimated IQ score in the study 
of Maddrey et al. (5) was 75 (range, 54-110), which was signifi-
cantly lower than our mean score of 90.2. In addition, the mean 
FSIQ, VIQ, and PIQ scores were lower (by 10 points) than those 
in our study.
 In order to understand the discrepancies between our results 
and those of the study of Maddrey et al. (5), other factors need 
to be considered. For example, the radiation dose could con-
tribute to the differences in the results. The median radiation 
dose in the study of Maddrey et al. (5) was 3,800 cGy, whereas 
most of the patients in our study received doses less than 3,000 
cGy, and only 7 patients received radiation doses over 3,600 cGy. 
The standard radiotherapy dose in earlier studies was 3,600 cGy 
for the craniospinal axis and 5,400 cGy for the posterior fossa 
(26). However, a higher radiation dose and younger age at the 
time of radiation are factors that have been shown to lower IQ. 
Thus, the total delivered radiation doses have been decreasing 
in recent clinical trials.
 According to the recent report, larger boost volumes in addi-
tion to the higher radiation doses were also associated with poor 
intellectual outcomes in patients with medulloblastoma (27). 
Boost to the posterior fossa delivers more radiation to struc-
tures located outside the targeted area than a boost limited to 
the tumor bed, thus resulting in a more decline of IQ scores. In 
our study, only 3 patients received boost radiation so that fur-
ther analysis regarding boost volumes was not conducted. Data 
of radiation volumes and doses are both needed to be collected 
for further studies.
 Another explanation for the differences in the IQs between 
the two studies might be the difference in the percentages of 
long-term survivors who were included in the studies. Maddrey 
et al. (5) enrolled only patients who had survived for over 10 
years, whereas only 11% of the patients in our study were long-
term survivors. A decrease in the IQ of a patient is probable if 10 
years or longer have passed after since the first diagnosis. This 
idea has also been suggested by other studies, including those 
by Palmer et al. (26) and Ris et al. (28). The study by Palmer et 
al. (26) evaluated 44 pediatric patients with histologically prov-
en medulloblastoma who were diagnosed before the age of 17 
and who survived more than 2 years. They obtained a mean es-
timated FSIQ of 83.57, which was more than 1 standard devia-
tion below the expected population norm. They suggested that 
the patients lost 2.55 mean points per year on the estimated 
FSIQ (P = 0.0001), 2.66 mean points on the VIQ (P = 0.0001), 
and 1.34 mean points on the PIQ (P < 0.001). Ris et al. (28) as-
sessed 43 patients with medulloblastoma who had a mean age 
of 6 years at diagnosis (range, 3-15 years). The score changes 
were estimated to be -4.3 FSIQ points, -4.2 VIQ points, and -4.0 
nonverbal scale IQ points per year. They suggested that the in-
tellectual losses of these patients were substantial but that some 
degree of intellectual preservation was possible compared with 
the impairments associated with radiation with conventional 
doses. Long-term studies of the changes in intelligence that oc-
cur according to age and radiation dose in long-term Korean 
survivors of medulloblastomas are necessary to better under-
stand these IQ changes.
 Our study showed that, in these patients, verbal function was 
higher than nonverbal function. The relative strengths of these 
patients in language skills may influence others to overestimate 
these individuals’ abilities. Thus, the expectations of the perfor-
mances of these patients may exceed their actual cognitive ca-
pacities (5).
 For memory, the mean scores on all of the RKMT indices of 
both verbal and nonverbal memory function that were assessed 
in this study were below the standardization sample scores. The 
mean verbal delayed recall score of the survivors of childhood 
medulloblastoma was 7.9, which was at the low average level. 
In the visual memory tasks, the mean scores of both immediate 
and delayed recall were 7.7 and 7.5, which were also at the low 
average level. We could not compare the mean recall scores with 
Yoo HJ, et al. • Neuropsychological Outcome of Survivors of Childhood Medulloblastoma
http://jkms.org  1733http://dx.doi.org/10.3346/jkms.2016.31.11.1726
the mean recognition task scores because we did not have a rec-
ognition task in the RKMT. In contrast to our results, Maddrey 
et al. (5) found both verbal and nonverbal deficits in their 10-
year survivors, with more severe deficits in nonverbal memory.
 The mean visual copy score on the RCFT, which assesses vi-
suospatial function (copying as accurately as possible), in the 
patient group in our study was 9.5, which was at the average 
level. In contrast, the 10-year survivors of childhood medullo-
blastomas in the report of Maddrey et al. (5) showed deficits in 
the visuospatial test requiring the RCFT copy task.
 The performances of the patient groups in our study were in-
consistent in the various neurocognitive functions. The mean 
digit symbol score suggested a processing speed of 6.2, which 
was within the borderline level (29). The mean score on the 
digit span forward test that assessed verbal attention was 9.8, 
which was at the average level, while the T score on the CTT 1 
that measured visual attention was 34.28, which was a mild to 
moderate deficit (12). In 1 executive function measure on the 
COWA, we were not able to compare the results with a standard-
ization sample because no Korean norm data for the COWA ex-
ist. The mean score on the digit span backward, which is anoth-
er measure of verbal executive function, was 6, which was with-
in the borderline level, whereas the T score on the CTT 2 that 
measures visual executive function was 32.18, which indicated 
a mild to moderate deficit.
 We analyzed the patients’ neurocognitive data by comparing 
groups that were divided according to the initial risk, radiation 
dose, age at diagnosis, or time after diagnosis. Of these results, 
statistical differences were only found in the analysis that com-
pared the groups according to the age at diagnosis. These re-
sults were consistent with those of previous reports that neuro-
cognitive changes were related to the patients’ ages at their first 
exposure to radiation. According to the study conducted by Pal-
mer et al. (26), patients with medulloblastomas who were youn-
ger than 8.02 years when they started to receive craniospinal ir-
radiation were at greater risk for cognitive decline than patients 
with medulloblastomas who were older (> 8.02 years) at the 
time of their craniospinal irradiation.
 When we compared the neuropsychological functions of these 
patients by their age at diagnosis (< 8 or ≥ 8 years old), we found 
significant group differences in intelligence, memory, executive 
function, visuospatial function and simple motor function, which 
suggested that these neurocognitive measures were sensitive to 
the effects of age at diagnosis and craniospinal irradiation (18).
 We examined whether there would be any differences ac-
cording to age at diagnosis (before 8 years old compared to af-
ter) with general well-being and brain-tumor specific tools in 
both patient and parent groups. No statistical differences were 
found between the age groups in both the patient and parent 
groups. The HRQOL evaluations of our patients and parents did 
not show significantly lower scores. The lack of dissatisfaction 
with these patients’ and parents’ lives may be due to their adap-
tation and habituation to the limitations that are often observed 
among children with chronic medical disorders (5).
 Our study had several limitations that restrict its interpreta-
tion as a cross-sectional study. First, we performed the neuro-
cognitive assessments only once, and we did not plan repeated 
assessments because of the various difficult clinical situations 
of the Korean survivors of childhood medulloblastoma. In ad-
dition, we only included consenting patients who were able to 
understand study concepts. Thus, our results do not represent 
Korean survivors of medulloblastomas as a whole, and patients 
who had relatively stable intellectual functions might be includ-
ed only. In addition, many other factors related to long-term 
complications were omitted from the analysis.
 However, this study is the first study to include a large group 
of Korean survivors of medulloblastoma. In addition, this study 
included brain tumor-specific QOL assessments that were con-
ducted by a specialized clinical neuropsychologist. In the fu-
ture, a longitudinal study that lasts for more than 10 years from 
the time of first diagnosis and that assesses the exact neurocog-
nitive changes in the patients’ visuospatial function, executive 
function, and attention is needed.
 This study is the first large-scale assessment of the neurocog-
nitive function and QOL of Korean survivors of childhood me-
dulloblastoma. The patients exhibited significant changes in 
their neurocognition in a wide range of functional domains. 
The patients who were under 8 years old at the time of first di-
agnosis exhibited deficits in intelligence, memory, executive 
function, and visuospatial function and not in attention and 
simple motor function, and these cognitive deficits might be 
related to the earlier exposures of these patients to craniospinal 
irradiation and chemotherapy. A long-term follow-up study in-
volving repeated assessments is needed in these patients after 
their first diagnosis in order to better understand the deficits of 
survivors of childhood medulloblastoma.
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